Objective  To investigate the effect of tigecycline on coagulation function and to provide a reference for the clinical rational use of tigecycline.

Methods  The data of patients treated with tigecycline in Shanghai Tenth People's Hospital between June 2019 and December 2023 by retrospective analysis. Statistical analysis was performed by collecting data on patients' basic information, routine coagulation parameters and thromboelastogram (TEG) parameters before and after the use of tigecycline.

Results  Activated partial thromboplastin time, prothrombin time and thrombin time were prolonged and fibrinogen levels were decreased with the use of tigecycline in 41 patients, the differences were statistically significant (P<0.05). There was no significant difference in levels of coagulation factor activation time , clot formation rate parameter, maximum angle of tangency, maximum amplitude of elastography  and coagulation index after treatment with tigecycline(P>0.05).

Conclusion  For patients with suspected coagulation abnormalities after tigecycline administration, a comprehensive assessment of coagulation should be made by combining routine coagulation indexes with TEG.

1.Yaghoubi S, Zekiy AO, Krutova M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review[J]. Eur J Clin Microbiol Infect Dis, 2022, 41(7): 1003-1022. DOI: 10.1007/s10096-020-04121-1.

2.Cruz-López F, Martínez-Meléndez A, Morfin-Otero  R, et al. Efficacy and in vitro activity of novel antibiotics for infections with carbapenem-resistant gram-negative pathogens[J]. Front Cell Infect Microbiol, 2022, 12: 884365. DOI: 10.3389/fcimb.2022.884365.

3.Guo M, Liang J, Li D, et al. Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database[J]. Thromb J, 2022, 20(1): 12. DOI: 10.1186/s12959-022-00369-z.

4.Campany-Herrero D, Larrosa-Garcia M, Lalueza-Broto  P, et al. Tigecycline-associated hypofibrinogenemia in a real-world setting[J]. Int J Clin Pharm, 2020, 42(4): 1184-1189. DOI: 10.1007/s11096-020-01072-7.

5.伏安,郭代红,高奥,等. 1 177例抗菌药物相关凝血障碍不良反应报告分析与风险信号挖掘[J]. 中国医院药学杂志, 2023, 43(1): 75-81. [Fu A, Guo DH, Gao A, et al. Analysis and signal mining in 1 177 reports of adverse drug rea-ctions related to antibacterial-induced coagulopath[J]. Chinese Journal of Hospital Pharmacy, 2023, 43(1): 75-81.] DOI: 10.13286/j.1001-5213.2023.01.12.

6.李丽宏. 血栓弹力图与凝血四项评价患者凝血功能的对比分析[J]. 中国医药指南, 2020, 18(5): 45. [Li  LH. Comparative analysis of thromboelast-ography and coagulation tetralogy in evaluating patients' coagulation funct-ion[J]. Guide of China Medicine, 2020, 18(5): 45.] DOI: 10.15912/j.cnki.gocm.2020.05.039.

7.缪颖波,赵强,宋颖,等. 血栓弹力图性能规范研究 [J]. 检验医学, 2022, 37(7): 680-683. [Miao  YB, Zhao Q, Song Y, et al. Research on performance speci-fication of thrombelastogram[J]. Laboratory Medicine, 2022, 37(7): 680-683.] DOI: 10.3969/j.issn.1673-8640.2022.07.016.

8.国家药品监督管理局. 个例药品不良反应收集和报告指导原则[S/OL]. (2018-12-19) [2020-09-10]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/ypggtg/ypqtggtg/20181221172901438.html.

9.王莉,李波,王枭,等. 分析急性重症创伤患者凝血功能障碍与病情严重程度及预后的关系[J]. 中华急诊医学杂志, 2020, 29(6): 826-828. [Wang L, Li B, Wang X, et al. The relationship between coagulation dysfunction and severity and prognosis of acute severe trauma patients[J]. Chinese Journal of Emergency Medicine, 2020, 29(6): 826-828.] DOI: 10.3760/cma.j.issn.1671-0282.2020.06.017.

10.王小华,刘红,汪燕燕,等. 某院64例替加环素临床应用回顾性分析[J]. 药物流行病学杂志, 2021, 30(7): 461-466. [Wang XH, Liu H, Wang YY, et al. Retrospective analysis of clinical application of tigecycline in 64 hospitalized patients[J]. Chinese Journal of Pharmacoepidemiology, 2021, 30(7): 461-466.] DOI: 10.19960/j.cnki.issn1005-0698.2021.07.007.

11.De Rosa S, Greco M, Rauseo M, et al. The good, the bad, and the serum creatinine: exploring the effect of muscle mass and nutrition[J]. Blood Purif, 2023, 52(9-10): 775-785. DOI: 10.1159/000533173.

12.Yu Z, Zhao Y, Jin J, et al. Prevalence and risk factors of tigecycline-induced liver injury: a multicenter retrospective study[J]. Int J Infect Dis, 2022, 120: 59-64. DOI: 10.1016/j.ijid.2022.04.024.

13.李颖,乔逸,王洁,等. 注射替加环素导致凝血功能异常4例[J]. 中国医院药学杂志, 2020, 40(2): 239-240. [Li Y, Qiao Y, Wang J, et al. Four cases of coagulation abnormality caused by tigecycline injection[J]. Chinese Journal of Hospital Pharmacy, 2020, 40(2): 239-240.] DOI: 10.13286/j.1001-5213.2020.02.22.

14.Liu J, Yan Y, Zhang F. Risk factors for tigecycline-associated hypofibrinogenemia[J]. Ther Clin Risk Manag, 2021, 17: 325-332. DOI: 10.2147/TCRM.S302850.

15.Wang D, Lin C, Gu C, et al. Tigecycline-associated coagulopathy: a single center retrospective analysis[J]. Pharmacology, 2022, 107(9-10): 524-536. DOI: 10.1159/ 000525380.

16.陈晓文,高杏. 73例替加环素对重症感染患者凝血功能影响的分析[J]. 中国处方药, 2022, 20(10): 92-93. [Chen XW, Gao X. Analysis of the effect of tigecycline on coagulation function in 73 patients with severe infection[J]. Journal of China Prescription Drug, 2022, 20(10): 92-93.] DOI: 10.3969/j.issn.1671-945X.2022.10.033.

17.Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels[J]. Antimicrob Agents Chemother, 2015, 59(3): 1650-1655. DOI: 10.1128/AAC. 04305-14.

18.何嘉豪,江倩,刘春丽. 血栓弹力图与传统凝血功能检测的相关性与一致性分析[J]. 实用医学杂志, 2022, 38(5): 606-610. [He JH, Jiang Q, Liu CL. Correlation and clinical value of thromboelastography and conventional coagulation tests[J]. Journal of Practical Medicine, 2022, 38(5): 606-610.] DOI: 10.3969/j.issn.1006-5725.2022. 05.016.

19.Whitton TP, Healy WJ. Review of thromboelastography (TEG): medical and surgical applications[J]. Ther Adv Pulm Crit Care Med, 2023, 18: 29768675231208426. DOI: 10.1177/29768675231208426.

20.Karon BS. Why is everyone so excited about thromboelastrography (TEG)?[J]. Clin Chim Acta, 2014, 436: 143-148. DOI: 10.1016/j.cca.2014.05.013.

21.张明,王瑾,王睿,等. 替加环素致凝血功能障碍文献分析[J]. 中国新药杂志, 2021, 30(3): 285-288. [Zhang M, Wang J, Wang R, et al. Literature analysis of tigecycline-induced blood coagulation dysfunction[J]. Chinese Journal of New Drugs, 2021, 30(3): 285-288.] DOI: 10.3969/j.issn. 1003-3734.2021.03.016.

22.Kujovich JL. Coagulopathy in liver disease: a balancing act[J]. Hematology Am Soc Hematol Educ Program, 2015, 2015: 243-249. DOI: 10.1182/asheducation-2015.1.243.

23.李鑫,张芳晓,章志丹. 严重肝功能障碍的出凝血问题[J]. 中国实用内科杂志, 2021, 41(6): 486-489. [Li X, Zhang FX, Zhang ZD. Coagulation and bleeding problems in severe liver dysfunction[J]. Chinese Journal of Practical Internal Medicine, 2021, 41(6): 486-489.] DOI: 10.19538/j.nk2021060107.